<link rel="stylesheet" href="styles.cf390c6bfbe7555f.css">

Preoperative risk stratification in endometrial cancer using ESGO/ESTRO/ESP 2021 guidelines: accuracy with and without molecular classification

dc.contributor.authorBretová, P.
dc.contributor.authorNdukwe, M.I.
dc.contributor.authorLaco, J.
dc.contributor.authorVosmiková, H.
dc.contributor.authorReslová, T.
dc.contributor.authorPohanková, D.
dc.contributor.authorBalcarová, K.
dc.contributor.authorHaviger, Jiří
dc.contributor.authorHavigerová, Jana Marie
dc.contributor.authorSirák, I.
dc.date.accessioned2025-12-05T16:08:05Z
dc.date.available2025-12-05T16:08:05Z
dc.date.issued2025
dc.description.abstractBackground: The study aimed to evaluate the impact of integrating molecular classification with imaging-based preoperative staging on risk stratification prediction in endometrial cancer patients in accordance with ESGO/ESTRO/ESP (European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology) 2021 guidelines. Methods: A retrospective cohort of 143 endometrial cancer patients was analyzed to assess changes in preoperative risk stratification after incorporating molecular classification into clinical evaluation. Preoperative clinical staging was primarily based on transvaginal ultrasound imaging. The overall agreement between preoperative risk group estimates (with/without molecular classification) and final postoperative outcomes was assessed using weighted Cohen’s Kappa, with bootstrap 95% confidence intervals and quadratic weights. Results: The addition of molecular classification significantly improved preoperative risk stratification accuracy (from 59.4 to 73.4%), particularly for patients post-operatively classified as high-risk. Kappa values indicated an improvement in overall agreement between preoperative and postoperative risk stratification following the addition of molecular classification, from 0.551 (95% CI: 0.430–0.671) to 0.767 (95% CI: 0.675–0.849). The non-overlapping confidence intervals indicated statistical significance. Preoperative assessment without molecular input tended to underestimate risk stratification. However, 26.6% of patients remained misclassified due to other factors, mostly within the intermediate and high-intermediate risk groups. Conclusions: Incorporating molecular classification enhances preoperative risk stratification and has the potential to tailor surgical treatment. Further validation through prospective multicentric studies is needed to support our findings. © The Author(s) 2025.eng
dc.formatp. &quot;Article number: 1302&quot;
dc.identifier.doi10.1186/s12885-025-14741-5
dc.identifier.issn1471-2407
dc.identifier.obd43882184
dc.identifier.urihttp://hdl.handle.net/20.500.12603/2447
dc.language.isoeng
dc.peerreviewedyes
dc.publicationstatuspostprint
dc.publisherBioMed Central Ltd
dc.relation.ispartofBMC Cancer, volume 25, issue: 1eng
dc.relation.publisherversionhttps://bmccancer.biomedcentral.com/articles/10.1186/s12885-025-14741-5
dc.rights.accessOpen Access
dc.rights.licenseCC BY
dc.source.urlhttps://bmccancer.biomedcentral.com/articles/10.1186/s12885-025-14741-5
dc.subjectEndometrial cancereng
dc.subjectESGO/ESTRO/ESP 2021 guidelineseng
dc.subjectMolecular classificationeng
dc.subjectNext-generation sequencingeng
dc.subjectRisk stratificationeng
dc.subjectSentinel node biopsyeng
dc.subjectUltrasonographyeng
dc.titlePreoperative risk stratification in endometrial cancer using ESGO/ESTRO/ESP 2021 guidelines: accuracy with and without molecular classificationeng
dc.typearticle

Soubory

Původní svazek

Nyní se zobrazuje 1 - 1 z 1
Načítá se...
Náhled
Název:
s12885-025-14741-5.pdf
Velikost:
1,7 MB
Formát:
Adobe Portable Document Format